The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Neomorphic mutations driving hematological cancers
It is known that spliceosome gene mutations can drive hematological cancers, but there may also be neomorphic mutations at play. In this video, recorded at the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Omar Abdel-Wahab, MD, from the Memorial Sloan Kettering Cancer Center, New York, NY, talks about other essential biological pathways that can potentially drive disease if mutated, such as the nuclear export protein XPO1/CRM1. Dr Abdel-Wahab also alludes to a talk regarding co-existing mutations that we can expect at the American Society of Hematology (ASH) 2017 annual meeting.
